Restless legs syndrome (RLS), now also called Willis-Ekbom disease, is a sensorimotor disorder marked by an irresistible urge to move the legs, usually paired with uncomfortable sensations that worsen at night. The condition affects an estimated 7 to 10 percent of US adults, with about 2 to 3 percent experiencing symptoms severe enough to disrupt sleep and daily function, according to the NINDS. Despite its prevalence, RLS is frequently missed or mistaken for anxiety, peripheral neuropathy, or simple insomnia. The good news is that it is one of the more treatable problems in clinical neurology — and the recommended approach to treating it has shifted meaningfully in recent guidance, which we cover in detail below.
Diagnostic Criteria
RLS is a clinical diagnosis based on five established criteria. All must be present: an urge to move the legs, usually with unpleasant sensations; symptoms that begin or worsen during periods of rest or inactivity; symptoms that are partially or totally relieved by movement; symptoms that worsen in the evening or night; and symptoms not solely accounted for by another medical or behavioral condition. There is no blood test or scan that “proves” RLS — the diagnosis rests on this history, which is why an accurate description of your symptoms matters so much.
Patients describe the sensation in colorful and varied ways — creepy-crawly, fizzy, ants under the skin, electric currents, deep itching that cannot be scratched. The sensation is genuinely difficult to describe because it is unlike pain, numbness, or itch. About 80 percent of RLS patients also experience periodic limb movements of sleep (PLMS), repetitive leg jerks during sleep that can fragment rest for both the patient and a bed partner.
Two Major Categories
Primary RLS, also called idiopathic, has a strong genetic component. Roughly 40 to 60 percent of patients have a positive family history, and several genes (BTBD9, MEIS1, MAP2K5) have been linked to risk. Onset is often before age 45.
Secondary RLS arises from another condition. Iron deficiency is the single most important reversible cause — even when ferritin is technically in the normal range, levels under 75 ng/mL frequently coincide with symptomatic RLS. Other causes include end-stage renal disease (where RLS prevalence approaches 30 percent), pregnancy (especially the third trimester), peripheral neuropathy, multiple sclerosis, and various medications.
Drugs that can worsen RLS include most antidepressants (especially SSRIs, SNRIs, and mirtazapine), antihistamines like diphenhydramine, dopamine antagonists (some antiemetics and antipsychotics), and lithium, per the Mayo Clinic. Bupropion is one antidepressant that generally does not worsen RLS. Never stop a prescribed medication on your own to test this — bring the list to your clinician, who can weigh whether a substitution makes sense.
The Iron-Dopamine Connection
Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Brain iron deficiency — which can occur even with normal blood iron — appears central to RLS pathophysiology. This helps explain why correcting iron helps many patients and why the dopamine system is involved in the disorder.
Current guidance recommends checking ferritin, transferrin saturation, and a complete iron panel in everyone with RLS. When iron stores are low, repletion is a cornerstone of treatment — but the decision to supplement, the route (oral versus intravenous), and the target should be guided by your clinician based on your labs. Taking iron without testing is not advised: iron overload is possible and can be harmful, so supplement only under clinician direction after testing, not on the basis of symptoms alone.
Treatment Strategy
First-line, non-drug measures start with correcting iron deficiency when it is present and reviewing any medications that may be aggravating symptoms. Lifestyle measures — regular moderate exercise, a consistent sleep schedule, reduced caffeine and alcohol especially in the evening, leg massage, and warm or cool baths — help many mild cases and are recommended by MedlinePlus and the Cleveland Clinic.
For medication treatment, the field has shifted significantly, and this is the most important update for anyone with RLS or caring for someone who has it. Per updated American Academy of Sleep Medicine (AASM) 2024 guidance, dopamine agonists are no longer recommended as first-line therapy for RLS. The reasons are two serious long-term harms: augmentation (a paradoxical worsening of RLS driven by the drug itself) and impulse-control disorders (such as compulsive gambling, shopping, or eating) that can develop on dopaminergic drugs. In their place, alpha-2-delta calcium channel ligands — the gabapentinoids gabapentin enacarbil, gabapentin, and pregabalin — together with iron repletion when indicated, are now generally preferred first.
This is a genuine reversal from older practice, in which dopamine agonists (pramipexole, ropinirole, and the rotigotine patch) were routinely started first. Those drugs remain FDA-approved and can still have a role in selected situations, but they are now used far more cautiously and are not the automatic first choice. All of these medications — gabapentinoids, iron, and dopamine agonists alike — are prescription decisions that must be individualized by a clinician; there is no safe self-dosing plan, and this article deliberately does not provide dosages. If you are currently on a dopamine agonist, do not stop it abruptly on your own; talk with your prescriber about whether your regimen still fits current guidance. Because guidelines are periodically updated, it is always worth asking your clinician to confirm the current recommendation for your situation.
For patients whose RLS does not respond to first-line options, low-dose opioids (such as methadone or oxycodone) are reserved for refractory cases under specialty supervision and have shown durable benefit without significant augmentation in long-term follow-up, per the RLS National Opioid Registry. This is a specialist decision, not a routine step.
Augmentation: A Critical Concept
Augmentation is the most important complication of long-term dopamine agonist use, and it is the central reason those drugs have fallen out of first-line favor. With augmentation, symptoms start earlier in the day, spread to other body parts (arms, trunk), become more severe overall, and drive a push for escalating doses. Recognizing it matters because the fix is to taper or change the dopamine agonist — adding more medication makes things worse.
Patients who have been on dopamine agonists for years and notice morning symptoms, new arm involvement, or a creeping need for higher doses should be evaluated for augmentation. Transitioning to a gabapentinoid, addressing iron status, or, in refractory cases, moving to low-dose opioids resolves augmentation in most cases, though the transition can be uncomfortable and should be managed by a knowledgeable clinician. Alongside augmentation, prescribers now also counsel patients specifically about the risk of impulse-control disorders on dopaminergic drugs, and ask about new compulsive behaviors at follow-up visits.
Sleep, Mood, and Quality of Life
Severe RLS is genuinely debilitating. Sleep onset latency averages over an hour in untreated severe cases, and total sleep time can fall below 5 hours nightly. Daytime fatigue, depression, and anxiety are roughly two to three times more common in RLS patients than in the general population.
Cardiovascular implications are debated. Some large cohort studies have linked RLS and PLMS to elevated cardiovascular risk, though confounding by sleep deprivation and other factors complicates interpretation. The Cleveland Clinic notes that effective treatment improves not just sleep but mood and daytime function.
When to seek emergency care: RLS itself is not life-threatening. Seek immediate evaluation if you develop sudden severe leg weakness, new bowel or bladder dysfunction, unrelenting leg pain different from typical RLS sensations, or signs of a blood clot (one-sided swelling, calf pain, redness). These can indicate other conditions sometimes confused with RLS.
What to Avoid
Diphenhydramine — the active ingredient in many over-the-counter sleep aids and allergy medications — frequently worsens RLS and should generally be avoided; ask a pharmacist about non-sedating alternatives if you need allergy relief. Caffeine, alcohol, and nicotine all aggravate symptoms in many patients. Long flights and prolonged sitting can trigger evening flares; built-in movement breaks help. And, as above, avoid starting iron supplements on your own without testing.
Many clinicians recommend reviewing all medications with patients newly diagnosed with RLS, since simply stopping or substituting an offending drug sometimes resolves symptoms entirely. Our guide to chronic conditions highlights how medication review is foundational to managing many overlapping conditions, including peripheral neuropathy, which can be confused with RLS.
When to See a Doctor
Persistent leg sensations relieved by movement that disturb sleep at least three times a week deserve evaluation. So do new symptoms during pregnancy, on starting a new medication, or in the setting of kidney disease or anemia. Sleep specialists, neurologists, and increasingly primary care physicians familiar with current guidelines all manage RLS effectively.
Polysomnography is not required for diagnosis but is sometimes ordered to evaluate coexisting sleep apnea, periodic limb movement disorder, or refractory cases. Most patients can be diagnosed and started on treatment based on a careful history and basic labs, including an iron panel.
Frequently Asked Questions
What deficiency causes restless legs?
Iron deficiency — especially low brain iron, which can occur even with normal blood iron — is the most consistently identified deficiency in RLS. Ferritin levels under 75 ng/mL are associated with symptomatic RLS in many patients. Folate and B12 deficiencies also occur in some cases. Because iron overload can be harmful, ask your clinician to test your levels before supplementing rather than starting iron on your own.
Are dopamine agonists still used for RLS?
They remain FDA-approved but are no longer first-line. Per updated AASM 2024 guidance, dopamine agonists such as pramipexole, ropinirole, and rotigotine are used far more cautiously because of the risks of augmentation and impulse-control disorders; gabapentinoids and iron are now generally preferred first. If you are on one, do not stop it on your own — ask your prescriber whether your regimen still fits current guidance.
Does RLS get worse with age?
RLS often progresses gradually over decades, becoming more frequent and more severe in middle age and beyond. About a third of patients have symptoms several times a week by age 50. That said, many patients have lifelong mild symptoms that never require medication.
Why does RLS get worse at night?
The circadian pattern reflects a natural nightly dip in dopamine activity. Iron levels in the brain also fluctuate with circadian rhythms. Inactivity in bed compounds the effect by removing the relief that movement provides.
Can stress cause restless legs?
Stress does not cause RLS, but it can worsen symptoms and disrupt sleep — which then aggravates RLS in a vicious cycle. Anxiety and depression coexist with RLS more often than chance, and effective RLS treatment improves both sleep and mood for most patients.
The Bottom Line
Restless legs syndrome is common, often missed, and highly treatable when properly diagnosed. The first steps are checking iron status (with a ferritin target commonly above 75 ng/mL) and correcting it under clinical direction, reviewing medications that may be aggravating the condition, and addressing lifestyle factors. Crucially, medication treatment has changed: per updated AASM 2024 guidance, dopamine agonists are no longer first-line because of augmentation and impulse-control risks, and gabapentinoids plus iron repletion are now generally preferred. Patients who have been on dopamine agonists for years and are noticing earlier or more severe symptoms should be evaluated for augmentation, since the solution is rarely more medication. With informed, up-to-date care — and no self-dosing — the substantial sleep and quality-of-life burden of RLS is one of the more reversible problems in clinical neurology.
TL;DR: RLS is a clinical diagnosis (urge to move the legs, worse at rest and at night, relieved by movement). Iron deficiency is the key reversible driver, so clinicians check ferritin and an iron panel — but supplement iron only under a doctor’s direction after testing. Treatment guidance has changed: per updated AASM 2024 guidance, dopamine agonists are no longer first-line because of augmentation and impulse-control disorders, and gabapentinoids plus iron are now generally preferred. All medications are prescriber-directed; do not self-dose or stop a prescribed drug on your own. Verify the current recommendation with your clinician.
Medical disclaimer: This article is general education, not medical advice, and does not provide dosing instructions. Diagnosis and treatment of RLS — including iron supplementation and any prescription medication — must be directed by a qualified clinician. Always verify current guidance. In an emergency, call 911.
Sources
- MedlinePlus — Restless Legs (medlineplus.gov)
- NINDS — Restless Legs Syndrome (ninds.nih.gov)
- AASM — Treatment of RLS and PLMD in Adults: An AASM Clinical Practice Guideline (2024/2025) (aasm.org)
- Mayo Clinic — Restless Legs Syndrome (mayoclinic.org)
- Cleveland Clinic — Restless Legs Syndrome (clevelandclinic.org)
- RLS National Opioid Registry (pmc.ncbi.nlm.nih.gov)